phentolamine has been researched along with Afferent Pupillary Defect in 1 studies
Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.
phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karpecki, PM | 1 |
| Foster, SA | 1 |
| Montaquila, SM | 1 |
| Kannarr, SR | 1 |
| Slonim, CB | 1 |
| Meyer, AR | 1 |
| Sooch, MP | 1 |
| Jaber, RM | 1 |
| Charizanis, K | 1 |
| Yousif, JE | 1 |
| Klapman, SA | 1 |
| Amin, AT | 1 |
| McDonald, MB | 1 |
| Horn, GD | 1 |
| Lazar, ES | 1 |
| Pepose, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Cross-Over, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution to Reverse Pharmacologically Induced Mydriasis in Normal Healthy Subjects[NCT04024891] | Phase 2 | 32 participants (Actual) | Interventional | 2019-08-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in pharmacologically-induced mydriatic (maximum) pupil diameter at 2 hours post-treatment in the study eye. (NCT04024891)
Timeframe: 2 hours
| Intervention | mm (Least Squares Mean) |
|---|---|
| Phentolamine Mesylate Ophthalmic Solution 1% | -1.69 |
| Phentolamine Mesylate Ophthalmic Solution Vehicle | -0.69 |
Change from baseline (-1 hour) in Best Corrected Distance Visual Acuity at each time point (0 min, 30 mins, 1 hour, 2 hours, 6 hours) in Study Eye (NCT04024891)
Timeframe: 0 mins, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours
| Intervention | Letters Read (Mean) | |||||
|---|---|---|---|---|---|---|
| 0 mins | 30 mins | 1 hour | 2 hours | 4 hours | 6 hours | |
| Phentolamine Mesylate Ophthalmic Solution 1% | -0.45 | -0.55 | 0.29 | 0.65 | 1.06 | 0.45 |
| Phentolamine Mesylate Ophthalmic Solution Vehicle | -0.81 | -0.55 | -0.10 | 0.16 | 0.10 | 0.90 |
Conjunctival hyperemia at each timepoint (0 min, 30 min, 1 hour, 2 hours, 4 hours, 6 hours), for study eye; in all subjects. Scale 0-3 (None, Mild, Moderate, Severe) (NCT04024891)
Timeframe: 0 min, 30 min, 1 hour, 2 hours, 4 hours, 6 hours
| Intervention | score on a scale (0-3) (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (-1 hr) | 0 min | 30 min | 1 hr | 2 hr | 4 hr | 6 hr | |
| Phentolamine Mesylate Ophthalmic Solution 1% | 0.45 | 0.23 | 1.52 | 1.55 | 1.42 | 1.10 | 0.81 |
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 0.35 | 0.29 | 0.42 | 0.45 | 0.45 | 0.42 | 0.35 |
Change from baseline (-1 hour) in Distance Corrected Near Visual Acuity at each time point (0 min, 30 mins, 1 hour, 2 hours, 6 hours) in Study Eye (NCT04024891)
Timeframe: 0 mins, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours
| Intervention | LogMar (Mean) | |||||
|---|---|---|---|---|---|---|
| 0 mins | 30 mins | 1 hour | 2 hours | 4 hours | 6 hours | |
| Phentolamine Mesylate Ophthalmic Solution 1% | 0.14 | 0.09 | 0.05 | 0.03 | 0.00 | -0.02 |
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 0.13 | 0.09 | 0.07 | 0.00 | 0.01 | 0.00 |
Change in pharmacologically-induced mydriatic (maximum) pupil diameter at remaining timepoints (30 min, 1 hours, 4 hours, 6 hours) (NCT04024891)
Timeframe: 30 min, 1 hours, 4 hours, 6 hours
| Intervention | mm (Least Squares Mean) | |||
|---|---|---|---|---|
| 30 minutes | 1 hour | 4 hours | 6 hours | |
| Phentolamine Mesylate Ophthalmic Solution 1% | -0.06 | -0.77 | -2.83 | -3.24 |
| Phentolamine Mesylate Ophthalmic Solution Vehicle | -0.13 | -0.29 | -1.69 | -2.54 |
Percent of Subjects Achieving Pupil Diameter No More Than 0.5 mm Above Baseline by Time Point with either phenylephrine or tropicamide (NCT04024891)
Timeframe: 0 min, 1 hour, 2 hours, 4 hours, 6 hours
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| 0 min | 1 hour | 2 hour | 4 hour | 6 hour | |
| Phentolamine Mesylate Ophthalmic Solution 1% | 2 | 6 | 11 | 24 | 31 |
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 3 | 3 | 6 | 12 | 28 |
"Change from baseline (-1 hour) in accommodation at each time point (0 min, 2 hours, 4 hours) with Tropicamide and Phenylephrine~Worsening of accommodation is defined as an amplitude decrease of greater than 1 diopter compared to baseline" (NCT04024891)
Timeframe: 0 min, 2 hours, 4 hours
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dilated with Tropicamide, 0 min72524499 | Dilated with Tropicamide, 0 min72524500 | Dilated with Tropicamide, 2 hr72524499 | Dilated with Tropicamide, 2 hr72524500 | Dilated with Tropicamide, 4 hr72524499 | Dilated with Tropicamide, 4 hr72524500 | Dilated with Phenylephrine, 0 min72524499 | Dilated with Phenylephrine, 0 min72524500 | Dilated with Phenylephrine, 2 hr72524499 | Dilated with Phenylephrine, 2 hr72524500 | Dilated with Phenylephrine, 4 hr72524499 | Dilated with Phenylephrine, 4 hr72524500 | |||||||||||||
| Unchanged Accommodation | Changed Accommodation (≥1 D) | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 13 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 14 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 7 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 3 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 9 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 11 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 7 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 5 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 9 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 10 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 11 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 4 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 13 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 4 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution Vehicle | 2 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 12 | |||||||||||||||||||||||
| Phentolamine Mesylate Ophthalmic Solution 1% | 3 | |||||||||||||||||||||||
1 trial available for phentolamine and Afferent Pupillary Defect
| Article | Year |
|---|---|
Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial.
Topics: Accommodation, Ocular; Administration, Ophthalmic; Adolescent; Adrenergic alpha-Antagonists; Adult; | 2021 |